Understanding The Likely Population Impact Of New And Improved Influenza Vaccines
Funder
National Health and Medical Research Council
Funding Amount
$358,678.00
Summary
Influenza causes a large burden of death and disease each year, as well as disruptive pandemics. Vaccines that could protect against more than one season�s flu strains (including new pandemic viruses) would be highly desirable, and may be on the horizon. Our aim is to understand the likely impact of these new vaccines on the way flu viruses spread between people, and change from one season to the next. This information is needed to justify their introduction, and inform their best use.
The Role Of EBV And HHV-6 Infection In Demyelinating Disease With A Consideration Of Past UVR Exposure.
Funder
National Health and Medical Research Council
Funding Amount
$305,800.00
Summary
The marked increase in immune disorders over the past fifty years is thought to reflect modern environmental and lifestyle factors, rather than changes in diagnosis. The hypothesis that has the most evidence to support it is the 'hygiene hypothesis'. That is, that a reduction in early life infection among modern children leads to immune system dysfunction and thus an increase in immune disorders. Delayed child infection, particularly of Epstein-Barr Virus has been prospectively linked to multipl ....The marked increase in immune disorders over the past fifty years is thought to reflect modern environmental and lifestyle factors, rather than changes in diagnosis. The hypothesis that has the most evidence to support it is the 'hygiene hypothesis'. That is, that a reduction in early life infection among modern children leads to immune system dysfunction and thus an increase in immune disorders. Delayed child infection, particularly of Epstein-Barr Virus has been prospectively linked to multiple sclerosis (MS) risk. This project aims to document the role of herpes virus (EBV, HHV-6) infection in the onset of first demyelinating events, a precursor to MS. The strength of this proposal is that it lies within an existing study framework - the Ausimmune Study, allowing detailed exploration of related associations with latitude, early life infant contact and past sun exposure. The incidence of MS has doubled from 1.2-100,000 to 2.4-100,000 from 1961 to 1996 in Newcastle, Australia. Although incidence is low, the disease has a median age of first onset of 24 years and progresses to serious disability even with immunomodulatory therapy (50% will need assistance in walking within 13 years) thus the current prevalence of 1 per 1,000 adults in Tasmania and 0.8 per 1,000 in Newcastle represent a serious burden of morbidity.Read moreRead less
Behavioural, Virological And Immunological Factors Influencing Hepatitis C Virus Infection In Injecting Drug Users
Funder
National Health and Medical Research Council
Funding Amount
$963,437.00
Summary
The hepatitis C virus (HCV) is a major public health problem affecting over 170 million people worldwide. In Australia an estimated 157,000 people have HCV and are at risk of serious disease, and 16,000 new infections occur each year. Treating HCV-related disease is expensive, and this healthcare burden is projected to grow significantly in coming years. Almost all new HCV infections in Australia occur among injecting drug users (IDUs), and despite our world-leading prevention programs, the viru ....The hepatitis C virus (HCV) is a major public health problem affecting over 170 million people worldwide. In Australia an estimated 157,000 people have HCV and are at risk of serious disease, and 16,000 new infections occur each year. Treating HCV-related disease is expensive, and this healthcare burden is projected to grow significantly in coming years. Almost all new HCV infections in Australia occur among injecting drug users (IDUs), and despite our world-leading prevention programs, the virus is spreading. Consensus is emerging that the best hope for control of HCV and related disease lies in a vaccine; our research will lay much of the groundwork for its development. The applicants' research to date shows that IDUs are being infected with HCV more frequently than previously assumed, that many carry multiple strains, and that dominant strains vary rapidly in individuals over time. These results reinforce the view that our prevention methods will not reduce infection rates and that current anti-viral treatments are not the solution. Nevertheless, we also found that some IDUs remain free of HCV infection despite risky behaviour with infected associates; intensive study of the immune functioning of these persistently non-infected individuals holds promise for vaccine development. In our proposed research, a collaboration of leading Australian epidemiologists, virologists and immunologists, we will recruit 210 young IDUs and follow them regularly for two years. Recruits will describe their social networks and nominate IDUs with whom they inject, provide blood samples and be interviewed about their behaviour at 3-month intervals. Individuals with recent and resolved HCV infection, change of dominant strain and lack of infection despite risky behaviour will be identified and their blood analysed for genetic factors that may be linked to immune protection. The outcomes will be crucial to the development and trialling of a vaccine against HCV.Read moreRead less